Every material Form 8-K Septerna, Inc. has filed with the SEC since August 10, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Septerna, Inc. (Nasdaq: SEPN) said it selected SEP-204, an oral small molecule TSHR negative allosteric modulator, as a development candidate for Graves' disease and thyroid eye disease, and reported preclinical data ahead of a November 5, 2026 poster presentation at the American Thyroid Association meeting. The company plans to start a Phase 1 trial in healthy volunteers in the first quarter of 2027, but the filing reports no financial results or funding figures.
SEP-204 is designed for once-daily oral dosing, with a projected human half-life of approximately 20-40 hours.
Preclinical data showed selectivity of more than 1000-fold for TSHR over the related FSHR and LHR receptors.
In 28-day GLP toxicology studies in rats and dogs, SEP-204 was generally well tolerated.
Phase 1 trial initiation in healthy volunteers is planned for the first quarter of 2027.
Septerna, Inc. said its Board of Directors appointed Rajiv Patni, M.D., as Chief Medical Officer, effective August 24, 2026. Dr. Patni previously served as CEO of Judo Bio and as Chief Research and Development Officer at Reata Pharmaceuticals, and the filing says he has more than 25 years of experience in biopharmaceutical research, development and regulatory work.
Appointment effective August 24, 2026; announced in a press release on August 25, 2026
Dr. Patni most recently served as Chief Executive Officer of Judo Bio
Previously held Chief Medical Officer roles at Global Blood Therapeutics, Portola Pharmaceuticals, Adamas Pharmaceuticals and Actelion Pharmaceuticals
Filing states he has contributed to 10 regulatory agency approvals or label expansions
Septerna reported second-quarter 2026 results for the quarter ended June 30, 2026. Revenue rose to $26.7 million, almost all from the Novo Nordisk collaboration, and the net loss narrowed to $13.0 million from $24.8 million a year earlier, even as research and development expenses rose to $35.1 million. The company said its $516.5 million in cash is expected to fund operations at least into 2029, and it now expects Phase 1 data for SEP-479 in the first quarter of 2027.
Revenue of $26.7 million from the Novo Nordisk collaboration, compared with $0.1 million from Vertex in the second quarter of 2025.
Net loss of $13.0 million, or $0.29 per share, compared with $24.8 million, or $0.56 per share, a year earlier.
Research and development expenses of $35.1 million, up from $22.2 million; general and administrative expenses of $8.5 million, up from $6.9 million.
Cash, cash equivalents and marketable securities of $516.5 million at June 30, 2026, expected to fund operations at least into 2029.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Septerna, Inc. filing is on SEC EDGAR ↗. 8-K briefs of other companies →